FR2939045A1 - Composition, useful for e.g. preparing dietary supplements and treating metabolic endotoxemia, comprises milk thistle seed extract, green coffee bean extract, walnut extract, an extract of chicory root, Jerusalem artichoke or inulin powder - Google Patents
Composition, useful for e.g. preparing dietary supplements and treating metabolic endotoxemia, comprises milk thistle seed extract, green coffee bean extract, walnut extract, an extract of chicory root, Jerusalem artichoke or inulin powder Download PDFInfo
- Publication number
- FR2939045A1 FR2939045A1 FR0806785A FR0806785A FR2939045A1 FR 2939045 A1 FR2939045 A1 FR 2939045A1 FR 0806785 A FR0806785 A FR 0806785A FR 0806785 A FR0806785 A FR 0806785A FR 2939045 A1 FR2939045 A1 FR 2939045A1
- Authority
- FR
- France
- Prior art keywords
- extract
- composition according
- inulin
- green coffee
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 title claims abstract description 17
- 235000007542 Cichorium intybus Nutrition 0.000 title claims abstract description 8
- 235000009496 Juglans regia Nutrition 0.000 title claims abstract description 7
- 235000020234 walnut Nutrition 0.000 title claims abstract description 7
- 240000008892 Helianthus tuberosus Species 0.000 title claims abstract description 5
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 5
- 235000003230 Helianthus tuberosus Nutrition 0.000 title claims abstract description 4
- 240000007049 Juglans regia Species 0.000 title claims abstract description 4
- 229940106589 milk thistle seed extract Drugs 0.000 title claims abstract description 4
- 208000037487 Endotoxemia Diseases 0.000 title claims description 5
- 235000015872 dietary supplement Nutrition 0.000 title claims 8
- 244000298479 Cichorium intybus Species 0.000 title abstract description 5
- 241000533293 Sesbania emerus Species 0.000 title abstract 2
- 229940069765 bean extract Drugs 0.000 title abstract 2
- 229920001202 Inulin Polymers 0.000 claims description 14
- 229940029339 inulin Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 8
- 235000014571 nuts Nutrition 0.000 claims description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 235000013824 polyphenols Nutrition 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 4
- 229960004245 silymarin Drugs 0.000 claims description 4
- 235000017700 silymarin Nutrition 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000001905 cichorium intybus l. root extract Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000004609 intestinal homeostasis Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 5
- 241000723343 Cichorium Species 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 230000001539 anorectic effect Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 241000723377 Coffea Species 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 229940042126 oral powder Drugs 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000758789 Juglans Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 3
- 235000010841 Silybum marianum Nutrition 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 235000021283 resveratrol Nutrition 0.000 description 3
- 229940016667 resveratrol Drugs 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000758791 Juglandaceae Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000010036 cardiovascular benefit Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940096421 milk thistle extract Drugs 0.000 description 1
- 235000020727 milk thistle extract Nutrition 0.000 description 1
- 229940096402 milk thistle seed Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
DESCRIPTION L'invention se rapporte, d'une façon générale, à des compositions végétales antioxydantes, et qui à ce titre peuvent présenter des propriétés anti-inflammatoires pour l'intestin et la muqueuse intestinale, notamment parce qu'elles freinent l'expression de cytokines pro-inflammatoires et le métabolisme oxydatif des acides gras polyinsaturés. En particulier, l'invention se rapporte aux extraits de végétaux contenant des polyphénols antioxydants qui peuvent être habituellement utilisés dans d'autres domaines de la médecine comme la dermatologie, la lutte contre les effets de l'âge ou l'hypertension. L'objet des compositions selon l'invention est de s'opposer à la prise de poids corporel consécutive à l'inflammation chronique de l'intestin et à l' endotoxémie métabolique qui en résulte. L'inflammation participe à la défense de l'hôte contre les agents infectieux mais on lui reconnaît de plus en plus un rôle important dans la pathogénie de nombreuses maladies chroniques comme l'athérosclérose, le diabète, l'hypertension, et plus récemment dans l'obésité dont la prévalence devient extrêmement préoccupante dans la société occidentale où près d'un quart de la population est en surpoids. Des chercheurs ont proposé récemment qu'il pourrait exister un lien entre les microorganismes intestinaux et le développement de l'obésité. Selon cette hypothèse, des endotoxines lipopolysaccharidiques (LPS) provenant des bactéries gram négatif qui résident dans l'intestin créeraient une endotoxémie responsable d'une inflammation chronique de faible grade, elle-même responsable d'une augmentation de la masse adipeuse et des dépôts de graisse, hypothèse confortée par le fait que l'administration de LPS en perfusion chez la souris provoque une augmentation du poids corporel et de la masse adipeuse comparables à celles induites par un régime hyperlipidique. Dans ce contexte il a été suggéré que la manipulation des populations microbiennes coliques au profit des bifidobactéries pourrait constituer une approche du traitement de l'obésité (Ley RE et al., Nature, 2004, 444: 1022-3). Ainsi plus le nombre de bifidobactéries est élevé par rapport aux bactéries gram négatif dans la lumière colique, plus faible est l'augmentation du poids corporel et du tissu adipeux induite par un régime gras. Les compositions selon l'invention ont, elles, pour objet principal d'apporter dans le même temps des fibres alimentaires et des actifs anti-inflammatoires capables de diminuer la production des cytokines pro-inflammatoires en inhibant notamment le facteur de transcription NF-kappa B, dont l'expression est activée par les endotoxines bactériennes comme l'IL-2, l'IL-1 (alpha et bêta), le TNF-alpha et les molécules d'adhésion des leucocytes (E-sélectine, VCAM-1 et ICAM-1). De plus ces actifs anti-inflammatoires réduisent la 1 production des médiateurs lipidiques de l'inflammation (eicosanoïdes) en augmentant notamment le pouvoir anti-oxydant du plasma. Les compositions selon l'invention ont aussi pour objet de favoriser le développement intestinal des bifidobactéries. Des travaux récents chez l'animal ont montré que la flore intestinale est différente chez les sujets maigres et chez les sujets obèses suggérant qu'enrichir la lumière colique en bifidobactéries permet de perdre du poids. D'autres auteurs ont montré que la prise d'inuline permet de diminuer les valeurs de l'indice de masse corporelle et les mesures du tour de taille. Les compositions selon l'invention renferment dans ce but des extraits de racine de chicorée ou de topinambour riches en inuline ou, au choix, de l'inuline purifiée qui favorisent la croissance préférentielle des bifidobactéries et le retour à une homéostasie intestinale. Les produits aujourd'hui disponibles pour lutter contre le surpoids appartiennent soit à la prescription médicale et sont d'un maniement délicat en raison de leurs effets secondaires, soit à l'automédication ; ils sont alors pour la plus part, à base de caféine et interfèrent avec le système nerveux autonome. Il semble que leur efficacité soit limitée en particulier à cause de phénomènes de tachyphylaxie, qui conduisent à un épuisement de l'effet. Ainsi, la présente invention occupe-t-elle une nouvelle place de choix dans l'arsenal des produits destinés à faire perdre du poids. Extraits végétaux entrant dans les compositions selon l'invention : Extrait de graine de chardon-marie (silybum marianum, astéracées). Le chardon-marie dont on extrait la silymarine est la plante qui dispose du plus grand nombre d'études relatives à son intérêt dans les maladies du foie. Les flavono-lignanes (silymarine) de la graine de chardon-marie ont un puissant effet antioxydant et la capacité d'inhiber la migration et l'adhésion aux tissus des leucocytes. Ces propriétés suggèrent de puissantes propriétés anti-inflammatoires potentielles chez l'être humain des extraits de silybum marianum. Les doses utiles d'extrait de chardon-marie seront calculées de façon à apporter entre 50 et 300 mg par jour de silymarine. Extrait de graine de café vert (coffea divers, rubiacées). L'acide caféique et l'acide chlorogénique sont des composés polyphénoliques répandus dans le monde végétal en particulier dans les graines de café et de tournesol. En plus de leur activité antioxydante ces molécules sont inhibitrices de certaines enzymes impliquées dans l'inflammation comme la phospholipase A2. Les doses utiles d'extrait de café vert, de préférence décaféiné, sont calculées de façon à apporter entre 50 et 500 mg de polyphénols par dose de poudre orale. 2 Extrait de noix (juglans regia, juglandacées). Des études épidémiologiques ont mis en évidence de consistants bénéfices liés à la consommation de noix et de cacahuètes sur les risques de maladies coronariennes et les facteurs de risque associés. De même plusieurs études cliniques ont évalué les effets de différentes noix ou graines apparentées sur les lipides, les lipoprotéines et différents facteurs de risques cardiovasculaires incluant l'oxydation, l'inflammation et la réactivité des vaisseaux. Il ressort des ces études un effet bénéfique sur ces facteurs de risques. Toutefois l'abaissement du mauvais cholestérol observé sous régime noix est plus important que celui attendu sur la base d'équations dérivées des variations du simple profil d'acides gras du régime alimentaire. Ainsi, en plus d'un profil acides gras favorable, les noix contiennent des composés bioactifs qui peuvent expliquer les multiples bénéfices cardiovasculaires. D'autres micronutriments caractéristiques des noix comme des composés phénoliques tel que le resvératrol et l'acide ellagique et des acides aminés comme l'arginine pourraient largement contribuer à ce rôle protecteur. Par ailleurs, le resvératrol peut prévenir la résistance à l'insuline et réduire l'accumulation de lipides dans les adipocytes. Le resvératrol est un activateur de la sirtuine Sirt 1, enzyme impliquée dans l'utilisation et la régulation des apports énergétiques nutritionnels. L'activation de la Sirt 1, diminue et normalise le niveau de la glycémie, augmente la sensibilité à l'insuline, augmente le nombre et l'activité des mitochondries, diminue l'adiposité et pourrait contribuer à la perte de poids. Les doses d'extrait de noix, que l'extrait provienne du cerneau total ou délipidé (tourteau), sont calculées de façon à apporter 10 à 100 mg de polyphénols par dose de poudre orale. DESCRIPTION The invention relates, in a general manner, to antioxidant plant compositions, and which, as such, may have anti-inflammatory properties for the intestine and the intestinal mucosa, in particular because they slow down the expression of pro-inflammatory cytokines and the oxidative metabolism of polyunsaturated fatty acids. In particular, the invention relates to plant extracts containing antioxidant polyphenols which can be usually used in other fields of medicine such as dermatology, the fight against the effects of age or hypertension. The object of the compositions according to the invention is to oppose the body weight gain consecutive to the chronic inflammation of the intestine and the resulting metabolic endotoxemia. Inflammation contributes to the host's defense against infectious agents, but is increasingly recognized as an important pathogenesis in many chronic diseases such as atherosclerosis, diabetes, hypertension, and more recently in obesity, the prevalence of which is becoming extremely worrying in Western society, where nearly a quarter of the population is overweight. Researchers have recently proposed that there may be a link between intestinal microorganisms and the development of obesity. According to this hypothesis, lipopolysaccharide endotoxins (LPS) from gram-negative bacteria that reside in the gut would create an endotoxemia responsible for low-grade chronic inflammation, itself responsible for an increase in body fat and fat deposits. fat, hypothesis supported by the fact that the administration of LPS perfusion in mice causes an increase in body weight and body fat comparable to those induced by a hyperlipidic diet. In this context, it has been suggested that the manipulation of microbial populations in favor of bifidobacteria could be an approach to the treatment of obesity (Ley RE et al., Nature, 2004, 444: 1022-3). Thus, the higher the number of bifidobacteria compared to Gram negative bacteria in the colonic lumen, the lower is the increase in body weight and adipose tissue induced by a fat diet. The main object of the compositions according to the invention is, at the same time, to provide dietary fibers and anti-inflammatory active agents capable of reducing the production of pro-inflammatory cytokines by inhibiting, in particular, the NF-kappa B transcription factor. , whose expression is activated by bacterial endotoxins such as IL-2, IL-1 (alpha and beta), TNF-alpha and leukocyte adhesion molecules (E-selectin, VCAM-1 and ICAM-1). In addition, these anti-inflammatory active agents reduce the production of lipid mediators of inflammation (eicosanoids), in particular by increasing the antioxidant power of the plasma. The compositions according to the invention also have the object of promoting the intestinal development of bifidobacteria. Recent work in animals has shown that the intestinal flora is different in lean subjects and in obese subjects suggesting that enriching the colonic light bifidobacteria can lose weight. Other authors have shown that the use of inulin decreases body mass index values and waist circumference measurements. The compositions according to the invention contain, for this purpose, inulin rich chicory or topinambur root extracts or, optionally, purified inulin which promote the preferential growth of bifidobacteria and the return to intestinal homeostasis. The products currently available to fight against overweight belong either to the medical prescription and are a delicate handling because of their side effects, or self-medication; they are then for the most part, caffeine-based and interfere with the autonomic nervous system. It seems that their effectiveness is limited especially because of phenomena of tachyphylaxis, which lead to an exhaustion of the effect. Thus, the present invention occupies a new place of choice in the arsenal of products intended to lose weight. Plant extracts used in the compositions according to the invention: Milk thistle seed extract (silybum marianum, asteraceae). The milk thistle from which silymarin is extracted is the plant with the largest number of studies related to its interest in liver diseases. The flavono-lignans (silymarin) of the milk thistle seed have a powerful antioxidant effect and the ability to inhibit migration and adhesion to leukocyte tissue. These properties suggest potent potential anti-inflammatory properties in humans of silybum marianum extracts. The useful doses of milk thistle extract will be calculated to provide between 50 and 300 mg per day of silymarin. Green coffee seed extract (various coffea, rubiaceous). Caffeic acid and chlorogenic acid are polyphenolic compounds widespread in the plant world, particularly in coffee and sunflower seeds. In addition to their antioxidant activity these molecules are inhibitory of certain enzymes involved in inflammation such as phospholipase A2. Useful doses of green coffee extract, preferably decaffeinated, are calculated to provide between 50 and 500 mg of polyphenols per dose of oral powder. 2 Walnut extract (juglans regia, juglandaceae). Epidemiological studies have shown consistent benefits from eating nuts and peanuts on coronary heart disease risk and associated risk factors. Similarly, several clinical studies have evaluated the effects of different nuts or related seeds on lipids, lipoproteins and various cardiovascular risk factors including oxidation, inflammation and vessel reactivity. These studies show a beneficial effect on these risk factors. However, the lowering of the bad cholesterol observed under the nut diet is greater than that expected on the basis of equations derived from the variations of the simple fatty acid profile of the diet. Thus, in addition to a favorable fatty acid profile, nuts contain bioactive compounds that can explain the multiple cardiovascular benefits. Other micronutrients characteristic of walnuts such as phenolic compounds such as resveratrol and ellagic acid and amino acids such as arginine could contribute significantly to this protective role. In addition, resveratrol can prevent insulin resistance and reduce lipid accumulation in adipocytes. Resveratrol is an activator of sirtuin Sirt 1, an enzyme involved in the use and regulation of nutritional energy intakes. Activation of Sirt 1 decreases and normalizes the blood glucose level, increases insulin sensitivity, increases the number and activity of mitochondria, decreases fatness and may contribute to weight loss. The doses of walnut extract, the extract comes from the total kernel or delipidated (cake), are calculated to provide 10 to 100 mg of polyphenols per dose of oral powder.
Fibres alimentaires poly-osidiques et inulines. Poly-osidic and inulin food fibers.
Des données récentes mettent en évidence le rôle de plus en plus important de l'intestin et en particulier du colon dans l'entretien d'une bonne santé. Il existe une importante symbiose entre l'écosystème microbien et l'épithélium intestinal qui est essentielle non seulement pour le bon fonctionnement de l'intestin mais aussi pour le fonctionnement de l'organisme dans sa globalité. Pour que le colon fonctionne correctement il doit contenir un écosystème microbien dont la composition est un élément déterminant de son activité en faveur du bien-être. Les fibres alimentaires encore appelées prébiotiques sont des composés dont la fermentation sélective induit des modifications spécifiques de la composition et de l'activité de la microflore intestinale avec comme conséquence des bénéfices pour le bien-être et la santé de l'hôte. Un des effets physiologiques bien établi est que les fibres alimentaires en 3 général et l'inuline en particulier permettent une moindre disponiblité et donc une moindre absorption des nutriments énergétiques à partir de la ration alimentaire. Les recommandations nutritionnelles internationales recommandent de consommer, pour un adulte, environ 30 grammes par jour de fibres dans la ration alimentaire alors que dans la société occidentale, la quantité moyenne consommée serait de 12 à 18 grammes par jour. A ce jour des ingrédients alimentaires reconnus comme prébiotiques sont représentés par les inulines de type polymères du fructane que l'on appelle fructo-oligosaccharides, oligofructose ou plus simplement inuline et qui sont habituellement utilisés dans des aliments pour bébés et jeunes enfants. Ces produits sont également présents dans de nombreux produits grand public destinés à la perte de poids, mais il est clair que les quantités proposées aux consommateurs sont considérablement trop faibles pour pouvoir manifester une quelconque activité sur le tonus inflammatoire colique. L'invention se propose d'apporter les doses optimales de fibres alimentaires, permettant d'atteindre les recommandations nutritionnelles et par la même de faciliter la croissance des bifidobactéries dans la lumière colique, source de bien-être et de réduction de l'endotoxémie métabolique. L'invention se propose d'utiliser indifféremment de l'inuline ou des extraits végétaux qui la contiennent, comme la racine de chicorée ou de topinambour (cychorium intybus et helianthus tuberosum, astéracées), la quantité d'inuline ainsi apportée étant comprise ente 2 et 10 grammes par dose. Exemple de formule n°1 : Inuline 4 à lO g Extrait de graine de café vert 100 à 1000 mg Extrait de graine de chardon-marie 100 à 1000 mg Extrait de tourteau de noix 100 à 1000 mg Pour une dose de poudre orale à prendre à raison de 2 à 3 doses par jour 25 Exemple de formule n°2 : Inuline 4 à 10 g Extrait de graine de café vert 100 à 1000 mg Extrait de tourteau de noix 100 à 1000 mg Pour une dose de poudre orale à prendre à raison de 2 à 3 doses par jour 30 Exemple de formule n°3 : Extrait de racine de chicorée 5 à 20 g Extrait de graine de café vert 100 à 1000 mg Extrait de tourteau de noix 100 à 1000 mg Pour une dose de poudre orale à prendre à raison de 2 à 3 doses par jour. 4 Recent data highlight the increasingly important role of the intestine and in particular the colon in the maintenance of good health. There is an important symbiosis between the microbial ecosystem and the intestinal epithelium which is essential not only for the proper functioning of the intestine but also for the functioning of the body as a whole. For the colon to work properly, it must contain a microbial ecosystem whose composition is a decisive element of its activity in favor of well-being. Dietary fiber, also called prebiotics, are compounds whose selective fermentation induces specific changes in the composition and activity of the intestinal microflora with consequent benefits for the well-being and health of the host. One of the well-established physiological effects is that dietary fiber in general and inulin in particular allow less availability and hence less absorption of energy nutrients from the diet. The international nutrition recommendations recommend that an adult consume about 30 grams of fiber per day in the diet, while in western society the average amount consumed is 12 to 18 grams per day. To date, food ingredients known as prebiotics are represented by the fructan polymer type inulins known as fructo-oligosaccharides, oligofructose or more simply inulin and which are usually used in foods for infants and young children. These products are also present in many consumer products for weight loss, but it is clear that the amounts offered to consumers are considerably too low to be able to manifest any activity on the inflammatory colonic tone. The invention proposes to provide the optimal doses of dietary fiber, making it possible to achieve the nutritional recommendations and thereby facilitate the growth of bifidobacteria in the colonic light, a source of well-being and reduction of metabolic endotoxemia. . The invention proposes to use indifferently inulin or plant extracts which contain it, such as chicory root or Jerusalem artichoke (cychorium intybus and helianthus tuberosum, asteraceae), the amount of inulin thus provided being included between 2 and 10 grams per dose. Example of Formula # 1: Inulin 4 to 10 g Green Coffee Seed Extract 100 to 1000 mg Thistle Seed Extract 100 to 1000 mg Nut Oil Extract 100 to 1000 mg For a dose of oral powder to be taken at a rate of 2 to 3 doses per day Example of Formula 2: Inulin 4 to 10 g Green coffee seed extract 100 to 1000 mg nut meal extract 100 to 1000 mg For a dose of oral powder to be taken at 2 to 3 doses per day Example of Formula 3: Chicory root extract 5 to 20 g Green coffee seed extract 100 to 1000 mg Walnut meal extract 100 to 1000 mg For a dose of oral powder take 2 to 3 doses a day. 4
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0806785A FR2939045B1 (en) | 2008-12-02 | 2008-12-02 | PHARMACEUTICAL AND NUTRITIONAL COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING COLON INFLAMMATION AND METABOLIC ENDOTOXEMIA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0806785A FR2939045B1 (en) | 2008-12-02 | 2008-12-02 | PHARMACEUTICAL AND NUTRITIONAL COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING COLON INFLAMMATION AND METABOLIC ENDOTOXEMIA |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2939045A1 true FR2939045A1 (en) | 2010-06-04 |
FR2939045B1 FR2939045B1 (en) | 2010-12-31 |
Family
ID=40897364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0806785A Active FR2939045B1 (en) | 2008-12-02 | 2008-12-02 | PHARMACEUTICAL AND NUTRITIONAL COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING COLON INFLAMMATION AND METABOLIC ENDOTOXEMIA |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2939045B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3094612A1 (en) * | 2019-04-05 | 2020-10-09 | Laboratoires Iphym | Composition comprising a green coffee extract and a superoxide dismutase (SOD) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020192202A1 (en) * | 2000-12-18 | 2002-12-19 | Probio Health | Probiotic compounds derived from lactobacillus casei strain KE01 |
WO2005058255A1 (en) * | 2003-12-18 | 2005-06-30 | Nestec S.A. | Composition for improving skin, hair and coat health containing flavanones |
US20050197495A1 (en) * | 2004-03-03 | 2005-09-08 | Naidu A. S. | Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions |
EP1591105A1 (en) * | 2004-03-17 | 2005-11-02 | Stada Arzneimittel Ag | Use of antioxidants for the preparation of pharmaceutical or cosmetic compositions for protecting the skin from damages by infrared-radiations |
US20070065396A1 (en) * | 2005-09-21 | 2007-03-22 | Tracie Martyn International, Llc | Topical macqui berry formulation |
US20080286254A1 (en) * | 2007-05-17 | 2008-11-20 | Kaneka Corporation | Composition comprising licorice polyphenol |
-
2008
- 2008-12-02 FR FR0806785A patent/FR2939045B1/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020192202A1 (en) * | 2000-12-18 | 2002-12-19 | Probio Health | Probiotic compounds derived from lactobacillus casei strain KE01 |
WO2005058255A1 (en) * | 2003-12-18 | 2005-06-30 | Nestec S.A. | Composition for improving skin, hair and coat health containing flavanones |
US20050197495A1 (en) * | 2004-03-03 | 2005-09-08 | Naidu A. S. | Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions |
EP1591105A1 (en) * | 2004-03-17 | 2005-11-02 | Stada Arzneimittel Ag | Use of antioxidants for the preparation of pharmaceutical or cosmetic compositions for protecting the skin from damages by infrared-radiations |
US20070065396A1 (en) * | 2005-09-21 | 2007-03-22 | Tracie Martyn International, Llc | Topical macqui berry formulation |
US20080286254A1 (en) * | 2007-05-17 | 2008-11-20 | Kaneka Corporation | Composition comprising licorice polyphenol |
Non-Patent Citations (2)
Title |
---|
HÄNSEL R., KELLER K., RIMPLER H., SCHNEIDER G.: "Hagers Handbuch der Pharmazeutischen Praxis 5 Drogen E-O", 1993, SPRINGER-VERLAG, GERMANY, XP002539480 * |
SEBAI HICHEM ET AL: "Protective effect of resveratrol in endotoxemia-induced acute phase response in rats.", ARCHIVES OF TOXICOLOGY APR 2009, vol. 83, no. 4, 27 August 2008 (2008-08-27), online, pages 335 - 340, XP002539479, ISSN: 1432-0738 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3094612A1 (en) * | 2019-04-05 | 2020-10-09 | Laboratoires Iphym | Composition comprising a green coffee extract and a superoxide dismutase (SOD) |
Also Published As
Publication number | Publication date |
---|---|
FR2939045B1 (en) | 2010-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2992933B1 (en) | Ginsenoside f2 for prophylaxis and treatment of liver disease | |
KR20180056972A (en) | Composition comprising a strain having formic acid producing ability for the preventing or treatment of obesity, or obesity-realated metabolic syndrome | |
JP6462918B2 (en) | Phytoecdysone for use in stabilizing weight after a weight loss diet | |
TWI610680B (en) | Olive extract containing Des Rhamnosyl Acteoside | |
WO2008140064A1 (en) | Nutrient composition for prevention and amelioration of lifestyle-related disease | |
KR101206543B1 (en) | A composition for preventing or treating of fatty liver comprising an extract of chestnut inner shell | |
JP2010111646A (en) | Treating agent for ulcerative colitis | |
EP2719291B1 (en) | Dietetic product for long-term administration to patients after bariatric surgery | |
FR2939045A1 (en) | Composition, useful for e.g. preparing dietary supplements and treating metabolic endotoxemia, comprises milk thistle seed extract, green coffee bean extract, walnut extract, an extract of chicory root, Jerusalem artichoke or inulin powder | |
JP6224899B2 (en) | Hypoglycemic agent | |
KR102390048B1 (en) | Composition for preventing or treating alcoholic fatty liver disease comprising fermented pyrus ussuriensis extract as an active ingredient | |
FR2687548A1 (en) | Novel low-calory dietetic composition | |
JP5118316B2 (en) | Obesity prevention / amelioration agent | |
CN110420270A (en) | A kind of functional composition containing camellia oil and fish oil and its application | |
JP6378926B2 (en) | Composition for lowering blood glucose level | |
JP5706142B2 (en) | Blood glucose lowering agent, visceral fat accumulation inhibitor, TG lowering agent, faecal fat excretion promoter containing ethanol extract of Fuyubodaiju flower as an active ingredient | |
WO2015028456A1 (en) | PPAR modulators | |
EP2719292B1 (en) | Medical nutrition product intended for being administered to obese persons recently operated in bariatric surgery | |
JP4445145B2 (en) | Oral composition | |
Hara et al. | In vivo evaluation of holocellulose and cellulose isolated from kumaizasa (Sasa senanensis) powder on bowel movements in rats | |
US20230106523A1 (en) | Quercetin enhancement formulation | |
Derosa et al. | Olea Europaea Effects on Glyco-Metabolic Parameters and on Glycemic Status in Patients with Impaired Fasting Glucose | |
JP2008179609A (en) | Agent for increasing adiponectin in blood | |
KR101402456B1 (en) | Composition for antiobesity comprising phytoncide and conjugated linoleic acid | |
WO2020029221A1 (en) | Composition with inhibiting fat formation and antioxidative activities and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 8 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
PLFP | Fee payment |
Year of fee payment: 10 |
|
PLFP | Fee payment |
Year of fee payment: 12 |
|
PLFP | Fee payment |
Year of fee payment: 13 |
|
PLFP | Fee payment |
Year of fee payment: 14 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
PLFP | Fee payment |
Year of fee payment: 16 |